IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#975
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$85M
Sean E. Browne
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and osteoinductive potential of human bone.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = XTNT ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$XTNT Xtant Medical Holdings, Inc. | 57 | 73 | 84 | 41 | 58.8x | 22.1x | -0.2% | -0.1% | 63.6% | 2.6% | -1.0% | 11.1% | 0.0% | 35.0x | $85M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Xtant Medical Holdings, Inc. (XTNT) receives a "Hold" rating with a composite score of 57.4/100. It ranks #975 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
120
HQ Base
BELGRADE, Montana
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for XTNT.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 73 | 84 | -11DRAG |
| MOMENTUM | 41 | 32 | +9ALPHA |
| VALUATION | 84 | 89 | -5NEUTRAL |
| INVESTMENT | 26 | 24 | +2NEUTRAL |
| STABILITY | 62 | 60 | +2NEUTRAL |
| SHORT INT | 85 | 93 | -8DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 30.6% vs WACC 8.8% (spread +21.8%)
GM 64% vs sector 44%, OM 3% vs sector 3%
Capital turnover 4.75x, R&D intensity 1.6%
Rev growth 11%, 10yr history
Interest coverage 2.8x, Net debt/EBITDA 2.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Xtant Medical Holdings, Inc. (XTNT) as a Hold with a composite score of 57.4/100 at a current price of $0.57. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Xtant Medical Holdings, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 57.4/100 places it at rank #975 in our full universe.
Narrow
Medium
Poor
Undervalued
Gross margins of 64% signal strong pricing power.
Value factor score of 84 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 58.8x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
Xtant Medical Holdings, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns Xtant Medical Holdings, Inc. a Hold rating, with a composite score of 57.4/100 and 3 out of 5 stars. Ranked #975 of 7,333 stocks, XTNT presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
XTNT earns a quality score of 73/100, indicating above-average business quality. The company reports a return on equity of -0.2% (sector avg: -1.9%), gross margins of 63.6% (sector avg: 44.1%), net margins of -1.0% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
XTNT carries a solid value score of 84/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 58.76x, an EV/EBITDA of 22.15x, a P/B ratio of 1.61x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
Xtant Medical Holdings, Inc.'s investment score of 26/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 11.1% vs. a sector average of 6.7% and a return on assets of -0.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
XTNT is currently showing below-average momentum at 41/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 11.1% year-over-year, while a beta of 0.61 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 62/100, XTNT exhibits average financial resilience. Key stability metrics include a beta of 0.61 and a debt-to-equity ratio of 35.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
XTNT's short interest factor score of 85/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 35.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $85M, Xtant Medical Holdings, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Xtant Medical Holdings, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #975 of 7,333 overall (87th percentile). Key comparisons include ROE of -0.2% exceeding the -1.9% sector median and operating margins of 2.6% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While XTNT currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Short Int. (85) vs Investment (26) — closing this gap could shift the rating.
EV/EBITDA 93% ABOVE SECTOR MEDIAN
ROE 89% BELOW SECTOR MEDIAN
Gross Margin 44% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
LAGUNA HILLS, Calif., February 20, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA.
LAGUNA HILLS, Calif., February 04, 2026--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology.
LAGUNA HILLS, Calif., February 02, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, UT.
There wouldn't be many who think C-MER Medical Holdings Limited's ( HKG:3309 ) price-to-sales (or "P/S") ratio of 0.9x...
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™.